BALTIMORE, Nov. 29 /PRNewswire/ -- Classen Immunotherapies, Inc. announces it has filed a patent infringement suit against King Pharmaceuticals, Inc. (Bristol, Tennessee), Elan Pharmaceuticals, Inc. (South San Francisco, California) and Elan Corporation, PLC (Dublin, Ireland) alleging the companies have infringed Classen Immunotherapies' patented processes directed to the discovery, analysis and commercialization of adverse drug event information. The complaint alleges that the defendants have sold more than $500 million worth of products - specifically, the muscle relaxant Skelaxin(R) (metaxalone) - that infringe Classen Immunotherapies' United States Patents Nos. 6,584,472 and 6,219,674.
Classen Immunotherapies has expertise in the area of discovering adverse event information that drug manufacturers are required to disclose.
More than two years after Classen Immunotherapies filed the application that resulted in U.S. Patent No. 6,219,674, Elan filed for and obtained two patents relating to new methods of use for metaxalone, including methods involving the disclosure of drug interaction events. King subsequently purchased the Elan patents and has used them in its efforts to remain the exclusive provider of Skelaxin(R). "King and Elan have proven that one can obtain a strong competitive advantage by patenting the disclosure of drug safety information," says Dr. J. Barthelow Classen, CEO of Classen Immunotherapies. "In this instance, however, we believe the methods used by King, Elan and their customers with respect to Skelaxin(R) fall within the scope of our earlier-filed patents."
For additional information concerning the lawsuit, please contact counsel for Classen Immunotherapies, Matthew G. McAndrews of Chicago-based Niro, Scavone, Haller & Niro, at (312) 236-0733 or e-mail email@example.com.
Skelaxin(R) is a registered trademark of Elan Pharmaceuticals.
Classen Immunotherapies, Inc.
CONTACT: Matthew G. McAndrews of Niro, Scavone, Haller & Niro,+1-312-236-0733 or e-mail firstname.lastname@example.org, for Classen Immunotherapies